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Abstract 
Gestational diabetes mellitus (GDM) is defined as glucose intolerance first diagnosed during the second or third 
trimester of pregnancy. The treatment aims at glycemic control through changes in the patient's diet with or without 
exercise, but some patients need insulin therapy. An alternative would be to use oral hypoglycemic agents such as 
glibenclamide (GLIB). The present study aims to analyze the toxic effects of GLIB in fetuses of pregnant rats which 
received  5  or  20mg/kg  doses  of  GLIB.  Glycemic  dosage  reveals  no  significant  difference  between  control 
(deionized  water)  and  treated  groups,  showing  that  these  concentrations  of  GLIB  were  not  effective  to  cause 
hypoglycemia in rats. The vitality of the fetuses in all groups was 100%. GLIB administration promoted increase in 
weight and significant changes in measures of external morphological parameters of treated fetuses. Histological 
analysis revealed that liver lobes, lobules and central lobular veins were well defined for all treatments. However, 
GLIB animals presented a light brownish precipitate into the center-lobular  veins and in the liver parenchyma 
among  the  hepatocytes.  These  results  indicated  a  possible  passage  of  the  drug  through  the  blood-placental 
membrane,  without  serious  changes  that  impair  the  development  of  neither  bone  tissue,  nor  the  liver  of  these 
animals. 
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Introduction 
Gestational diabetes mellitus (GDM) is a disease that 
can affect women during pregnancy. It is defined as 
glucose intolerance of variable degree with onset or 
first diagnosis during the second or third trimester of 
pregnancy (Rotondo and Coustan, 1996; Maganha et 
al., 2003). 
During  its  development,  maternal  hyperglycemia, 
which  reaches  the  fetuses  by  facilitated  diffusion 
(Aguilar-Bryan  et  al.,  1995),  stimulates 
overproduction  of  insulin  that  interferes  with  fetal 
homeostasis, might leading to macrosomia, trauma of 
the  birth  canal,  twisted  shoulder,  hypoglycemia, 
hyperbilirubinemia, hypocalcaemia and polycythemia 
fetal, neonatal respiratory disorders, blindness, kidney 
failure, and intrauterine fetal death (O`Sullivan et al., 
1973; Larimore and Petrie, 2000). 
The GDM treatment aims at glycemic control through 
changes in the patient's diet with or without exercise. 
Approximately 15 to 60% of women with GDM need 
insulin therapy (Bertini, 2000; Volpato et al., 2006). 
However insulin treatment is expensive, unwieldy and 
difficult to adhere. 
An  alternative  would  be  to  use  oral  hypoglycemic 
agents  such  as  the  glibenclamide  (GLIB),  a  second 
generation  sulfonylurea,  for  Diabetes  mellitus 
treatment.  GLIB  binds  to  the  SUR1  subunit  of  K
+ 
channel  sensitive  to  ATP  and  blocks  the  channel 
(Aguilar-Bryan  et  al.,  1995).  The  reduction  in  K
+ 
conductance  leads  to  membrane  depolarization  and 
Ca
2+  influx through  voltage  sensitive  Ca
2+ channels. 
The intracellular Ca
2+ acts as an insulin secretagogue 
(Aguilar-Bryan  et  al.,  1995)  thereby  producing 
hypoglycemic  action  by  increasing  insulin  release 
from pancreatic β cells (Nery et al., 2008). 
Although  some  drugs,  such  as  oral  hypoglycemic 
agents,  are  responsible  for  4-5%  of  fetal 
malformations (Luiz et al., 2011), studies with model 
human  placenta  showed  that  the  transfer  of  GLIB 
through  the  placental  barrier  is  negligible,  and  the 
fetuses’ drug concentration does not exceed more than 
1-2% of maternal concentration (Albuquerque, 2009). 
Given the importance of using an oral hypoglycemic 
agent in the treatment of GDM, and the need for more 
information on this drugs’ family (Luiz et al., 2011), 
the present research aims to study the toxic effects of 
GLIB  in  fetuses  of  pregnant  rats  which  received 
different doses of GLIB. 
Materials and Methods 
All experiments  were performed in accordance  with 
standards  established  by  the  Brazilian  Society  of 
Laboratory  Animal  Science  (SBCAL-old  COBEA). 
The  reagents  and  salts  used  were  obtained  from 
Sigma-Aldrich Chemicals laboratories, Synth, Merck http://www.openveterinaryjournal.com 
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and Bio Rad. Three female Wistar rats (weighing 180 
to 200g) were kept with one male for approximately 
12  hours.  The  pregnancy  was  confirmed  by  the 
presence  of  sperm  in  vaginal  lavage  obtained  with 
saline introduced into the vagina, indicating the first 
day of pregnancy. The pregnant rats  were separated 
from others in order to receive the drug. 
Glibenclamide  powder  (Pharmaceutical  Laboratory 
Galena - Lot: GC/002/4023) (GLIB) was prepared at 
the time of use, dissolved in 5 drops ethanol in 100 
mL of deionized water. The concentrations of 5 and 
20mg/kg were administered by oral gavage in the 1st, 
5th, 10th and 15th day of gestation. The same protocol 
was  used  for  control  animals  which  received  only 
deionized water. Rats from all groups were weighed in 
order to determine the volume to be administered. 
Glucose dosages of pregnant animals were determined 
before  GLIB  administration  and  30  minutes  after 
using  glucometer  strips  (MediSense  Optium  Xceed, 
Abbott). The feed intake and weight of pregnant rats 
were evaluated in the 1st, 5th, 10th, 15th and 18th day, 
using a semi analytical balance. 
After 18-19 days of pregnancy, cesarean sections were 
performed. The corpora lutea were carefully dissected 
for  subsequent  counting,  and  fetuses  were  removed 
with  their  placentas.  After  this  procedure,  the  rats 
were  sacrificed  by  deepening  the  anesthesia.  The 
following  parameters  were  analyzed:  number  of 
corpora  lutea  and  implantations,  number  of  live 
fetuses,  weights  of  fetuses  and  corresponding 
placentas. 
The fertility rate of rats was assessed by the following 
equations: 
Pre-implantation  loss  =  (number  of  corpora  lutea  – 
number of deployments) / number of corpora lutea. 
Post-implantation  loss  =  (number  of  deployments  – 
number of living fetuses) / number of deployments. 
Other  parameters  were  analyzed  as  deployment  of 
eyes and ears, limbs, anal drilling, girth, head injury, 
length and configuration of the tail and toes. 
Index  vitality  was  obtained  using  the  following 
equation: 
Number of living and lifeless ____ 100 % 
Number of living fetuses ________    x % 
After  this  macroscopic  inspection,  the  fetuses  were 
euthanized  by  halothane  inhalation,  weighted  and 
fixed in Bouin solution or diaphanized. 
Anatomic  measurements  were  performed  using  a 
caliper:  anteroposterior  skull,  lateral-lateral  skull, 
anteroposterior  chest,  lateral-lateral  thorax, 
craniocaudal  and  tail,  to  investigate  possible 
macrosomic changes. The results were represented by 
the average ±  standard deviation. Student t-test  was 
used to compare the means. The significance level was 
set at p<0.05. 
Diaphanized  fetuses  (xylene  and  alizarin  2%  in  1% 
KOH solution) were analyzed using a stereoscope to 
record  abnormalities  and  possible  variations  in  the 
ossification process. The results were compared to the 
illustrations  of  Damasceno  et  al.  (2008).  The 
remaining fetuses were fixed in Bouin, dehydrated in 
crescent series of ethanol, diaphanized in xylene and 
included in paraffin. 
The histological sections (5μm) were deparaffinized in 
xylene,  rehydrated  in  decreasing  ethanol  series  and 
stained with hematoxylin-eosin (HE). The slides were 
individually analyzed and the number of liver center-
lobular veins, partially or completely obstructed, was 
counted  in  attempting  to  ascertain  the  possible 
cytotoxicity of GLIB. The results were represented by 
the average of experiments ± standard deviation. One-
way ANOVA was used to compare the results. The 
significance  level  was  p<0.001.  Tukey’s  Multiple 
Comparison Test was also applied. 
Results 
Glycemic dosage, previously or subsequently to GLIB 
administration,  revealed  no  significant  difference 
between control and treated groups (p> 0.05), showing 
that these concentrations of GLIB were not effective 
to cause hypoglycemia in rats. The glycemic dosage of 
pregnant Wistar rats pre-treatment and post-treatment 
(30  minutes  after  GLIB  administration)  dosage  was 
less than 120mg/dL in all groups (data not shown). 
In  relation  to  feed  intake,  the  results  were  variable 
throughout  the  gestational  period,  but  the  rats  of 
control group had a lower intake of feed throughout 
the gestational period compared to the rats of treated 
groups. 
Regarding the weight gain, the values were variable 
throughout the  gestational period, but after the 15th 
day of pregnancy, weight gain for treated animals was 
significantly different when compared to control. The 
rats  treated  with  20mg/kg  GLIB  showed  significant 
increase  in  weight  gain  also  after  the  5th  day  of 
gestation (data not shown). 
The vitality of the fetuses in all groups was 100%. The 
pre-implantation  loss  in  the  treated  groups  was  not 
significantly different  from the control  group. In all 
groups,  absorptions  with  or  without  fetal  placentas, 
were  observed:  1  reabsorption  in  the  control,  4 
reabsorptions in the group treated with GLIB 5mg/Kg 
and 1 reabsorption in the group treated with 20mg/kg 
GLIB (data not shown). 
Regarding  fetuses  and  placentas  from  animals  of 
group GLIB 20mg/kg the weight was 2.5 ± 0.04 g and 
0.79 ± 0.02 g, respectively (Fig. 1). 
Considering the external morphological parameters, 5 
and  20mg/kg  GLIB  administration  promoted 
significant changes in measures when compared to the 
control group (Fig. 2-3). 
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Fig. 1. Average-weights of placentas and fetuses of pregnant 
rats exposed to 0.5mL/Kg of deionized water (control, n = 
53), 5mg/Kg GLIB (n = 47) and 20mg/Kg GLIB (n = 60). 
*p <0.05 compared to the control group. 
 
 
Fig. 2. Morphological parameters of fetuses of pregnant rats 
exposed to 0.5mL/Kg of deionized water (control, n = 26), 
5mg/Kg GLIB (n = 23) and 20mg/Kg GLIB (n = 30). The 
panel  represents  the  measurements  performed: 
anteroposterior  (A)  and  lateral-lateral  (B)  skull, 
anteroposterior (C) and lateral-lateral (D) of the chest, head-
tail (E) and tail (F). * p<0.05 when compared to the control 
group. 
 
 
Fig. 3. Diaphanized fetuses. (A) Control group, (B) 5mg/Kg 
GLIB group, (C) 20mg/Kg GLIB group. 
 
Histological  analysis  of  median  sagittal  section 
revealed that liver lobes, lobules and central lobular 
vein  were  well defined for all treatments. However, 
animals treated with GLIB presented a light brownish 
precipitate  into  the  center-lobular  veins  (partially  or 
totally)  and  in  the  liver  parenchyma  among  the 
hepatocytes (Fig. 4-5). 
 
 
Fig. 4. Histological features of the fetuses livers of pregnant 
rats exposed to 0.5mL/Kg of deionized water (control, n = 3) 
(A - 100x, B - 400x). V = central vein. 
 
 
Fig. 5. Histological features of fetuses livers of pregnant rats 
exposed to5mg/Kg GLIB (A, B, C) and 20mg/Kg GLIB (D, 
E, F). Note the presence of a brownish precipitate (*) in the 
lumen of the central vein (V) and in the liver parenchyma. 
Arrow = capillary sinusoid. A, D: 100x, B, C, E, F: 400x. 
 
The  control  animals  showed  100%  of  the  center-
lobular  veins  free  of  precipitate,  while  the  treated 
GLIB  5mg/Kg  group  showed  a  predominance  of 
center-lobular veins without precipitate and only 9% 
(corresponding to 3 veins) of the total center-lobular 
veins  with precipitate. Unlike GLIB 20mg/kg  group 
presented  a  light  brown  precipitate  in  43% 
(corresponding to 24 veins) of total veins. 
Discussion 
Considering the incidence and severity of GDM, the 
study of a new drug therapy became necessary. For 
these reasons GLIB, a second-generation sulfonylurea, 
has  been  shown  as  an  option,  considering  its  low 
permeability  throw  hematoplacental  barrier  (Silva  et 
al., 2007b). 
According to Aberg et al. (2001), glycemic control is 
particularly  important  to  reduce  perinatal 
complications  (Aberg  et  al.,  2001;  Valdés  et  al., 
2008). Comparative studies of glycemic control using 
GLIB  and  insulin  showed  that  18.75%  of  pregnant http://www.openveterinaryjournal.com 
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women  have  not  achieved  glycemic  control  with 
GLIB (Silva et al., 2007a). A study with 50 pregnant 
women with GDM and treated with glyburide showed 
58%  efficacy  (Silva  et  al.,  2007b).  However  the 
success  rate  of  using  glibenclamide  varies  greatly 
among  studies,  probably  due  to  the  use  of  different 
doses and protocols (Langer, 2002). 
The effectiveness of GLIB on glycemic control could 
be evaluated using glucose measurements before and 
after drug administration. The present study showed 
no significant differences between treated and control 
animals,  indicating  that  the  studied  doses  were  not 
able  to  change  the  normoglycemia  of  pregnant  rats 
(Valdés et al., 2008). 
The weight gain of animals exposed to any chemical 
agents  during  a  specific  period  is  a  parameter 
commonly  used  to  determine  their  toxic  effects 
(O`Sullivan et al., 1973). Experiments using 20mg/kg 
showed  weight  gain,  possibly  as  a  compensatory 
mechanism  for  hypoglycemic,  suggesting  that  this 
dose was able to increase insulin secretion, decrease 
hepatic production of glucose, resulting in reversal of 
hyperglycemia  and,  indirectly,  in  increased  insulin 
sensitivity  in  tissues  of  normoglycemic  individuals, 
simulating a fast. Consequently the hunger center can 
be  activated  and  the  individual  tends  to  feed 
unnecessarily and excessively, leading to weight gain 
(Guyton and Hall, 2006). 
Regarding  acute  toxicity  (Hellmuth  et  al.,  1994; 
Larimore  and  Petrie,  2000;  Albuquerque,  2009), 
reproductive capacity and physical development of rat 
fetuses  (Albuquerque,  2009),  the  pre-and  post-
implantation  blastocyst  undergoes  physiological 
changes  when  exposed  to  chemicals,  serving  this 
parameters  to  distinguish  embryotoxicity  of  direct 
toxic effects on uterine functions, which can influence 
fertility,  followed  by  pregnancy  prematurely 
interrupted, and possible fetal malformations (Khera, 
1984; Gerenutti et al., 2006). Results of treated groups 
showed corpora lutea with no corresponding fetuses. 
The presence of fetal reabsorptions indicates a failure 
in  embryonic  development,  probably  occasioned  by 
drug administration. 
The  rate  of  pre-implantation  losses  establishes  the 
relationship between two variables: number of corpora 
lutea and number of deployments. The size (or weight) 
of corpora lutea correlates with the concentration of 
circulating  progesterone  (Cumming,  1990),  which  is 
one  of  the  major  hormones  to  maintain  pregnancy 
(Uchida et al., 1970).  
It  is  known  that  the  rate  of  implantation  correlates 
with  the  number  of  corpora  lutea,  and  is  a  success 
indicator  of  blastocyst  implantation  into  the 
endometrium (Kato et al., 1979). 
Teratogenicity  is  characterized  by  retarded  fetal 
development with reduced fetal weight.  
The  implantation  of  the  blastocyst  in  pregnant 
mammals requires an integrated series of phenomena 
which  include  uterine  preparation,  embryo 
transportation,  embryonic  annexes,  uterine 
transformation, placental development and  hormonal 
system to support each step (Alivert et al., 1979; Ford, 
1982).  
As a fetal organ, the placenta is exposed to the same 
influences of intrauterine environment and any trauma 
affects the  fetuses (Damasceno et al., 2008). Proper 
placental functioning is crucial for the development of 
the fetuses, and the pattern of morphological alteration 
found  may  indicate  clinical  changes  related  to 
maternal and fetal intrauterine development. 
The placental barrier between mother and fetuses has 
a protective function, however limited, because many 
drugs  can  cross  it,  either  by  simple  diffusion, 
facilitated diffusion or active transport (Hagerman and 
Villee, 1960; Beebe et al., 1996). 
The fetuses of treated groups showed macrosomia (p 
<0.05  compared  to  control),  corroborating  to  other 
comparative  studies  with  insulin  and  GLIB,  which 
also  showed  macrosomia  for  GLIB  (Hagerman  and 
Villee, 1960).  
On  the  other  hand,  Langer  et  al.  (2000)  found  no 
difference  between  the  two  groups.  Literature  data 
show that maternal weight gain during pregnancy is 
associated with fetal macrosomia, even in the absence 
of  diabetes  mellitus,  because  obesity  induces  fetal 
hyperinsulinemia,  increased  plasma  triglycerides, 
increased  transplacental  transport  of  fatty  acids, 
justifying  such  morphological  changes  (Montenegro 
and Rezende, 2008). 
There was no significant increase in placental weight 
for control and treated groups. Comparing the findings 
with  human  placental  development,  the  placental 
weights in full-term fetuses represent 1/6 of their birth 
weight. The evolution of the placental weight during 
pregnancy in humans shows that, initially, the weight 
exceeds the conceptus, equaling around 14 weeks. So 
over the course of pregnancy the placenta undergoes 
involution, which is not a good parameter to evaluate 
embryonic  development  during  late  gestation 
(Montenegro and Rezende, 2008). 
Fetuses  undergoing  the  evisceration  and  clarifying 
techniques  showed  that  macroscopic  and  qualitative 
parameters of bone marrow remained unchanged in all 
experimental groups. Histological analysis of GLIB 5 
and 20mg/kg showed that there is no alteration in the 
fetuses  liver  histoarchitecture,  but  revealed  the 
presence of a light brownish precipitate in the central-
lobular vein, as well as in the liver parenchyma among 
the hepatocytes.  
This precipitate resembles glycoprotein expression on 
the  surface  membrane  of  liver  hepatocyte  in  rats 
submitted to polychemotherapy, suggesting a possible http://www.openveterinaryjournal.com 
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toxicity  of  glibenclamide  (Sen`kova  et  al.,  2012). 
These results indicated a possible passage of the drug 
through the blood-placental membrane, observed as a 
light brownish precipitate into the central-vein of the 
liver lobules. However, no serious anatomical changes 
that  impair  the  development  of  bone  tissue,  or  the 
anatomy and histology of the liver were observed in 
these animals. 
Acknowledgments 
The authors thank PIBIC/CNPq for financial support. 
___________________________________________ 
References 
Aberg, A., Rydhstrom, H. and Frid, A. 2001. Imparied 
glucose  tolerance  associated  with  adverse 
pregnancy  outcome:  a  population-based  study  in 
southern Sweden. Am. J. Obstet. Gynecol. 184 (2), 
77-83. 
Aguilar-Bryan,  L.,  Nichols,  C.G.,  Wechsler,  S.W., 
Clement, J.P., Boyd, A.E., González, G., Herrera-
Sousa, H., Nguy, K., Bryan, J. and Nelson, D.A. 
1995.  Cloning  of  the  beta  cell  high-affinity 
sulfonylurea  receptor:  A  regulator  of  insulin 
secretion. Science 268, 423-426. 
Albuquerque, L.B.L. 2009. Estudos in vitro e in vivo 
da Plathymenia reticulata Benth. [dissertação]. São 
Paulo:  Programa  de  Pós-Graduação  em  Ciências 
Farmacêuticas, Universidade de Sorocaba. 
Alivert, V., Bonanomi, L.,  Giavini, E., Leone, V.G. 
and  Mariani,  L.  1979.  The  extent  of  fetal 
ossification as an index of delayed development in 
teratogenic  studies  on  the  rat.  Teratology  20(2), 
237-242. 
Beebe, L.A., Cowan, L.D. and Altshuler, G. 1996. The 
epidemiology  f  placental  features:  associations 
with gestacional age and neonatal outcome. Obstet. 
Gynecol. 87, 771-778. 
Bertini,  A.M.  2000.  Diabetes  mellitus  e  gravidez. 
Federação Brasileira de Ginecologia e Obstetrícia. 
Tratado  de  obstetrícia.  São  Paulo:  Atheneu.556-
567. 
Cumming, A.M. 1990. Toxicological mechanisms of 
implantation  failure.  Fundam.  Appl.  Toxicol.  15, 
571-579. 
Damasceno,  D.C.,  Kempinas,  W.G.,  Volpato,  G.T., 
Consoni,  M.,  Rudge,  M.V.C.  and  Paumgartten, 
F.J.R.  2008.  Anomalias  congênitas:  estudos 
experimentais,  1
st  ed.  Belo Horizonte:  Coopmed. 
pp: 99. 
Ford,  W.C.L.  1982.  The  effect  of  deoxy-6-
fluoroglucose  on  the  fertility  of  male  rats  and 
mice. Contraception 25, 535-545. 
Gerenutti,  M.,  Del  Fiol,  F.  and  Groppo,  F.C.  2006. 
Performance reprodutiva de ratas grávidas e efeitos 
embriotóxicos da ciprofloxacina. Pharmazie 61(1), 
79-80. 
Guyton,  A.C.  and  Hall,  J.E.  2006.  Tratado  de 
Fisiologia  Médica.  11
th  ed.  Rio  de  Janeiro: 
Elsevier. 
Hagerman,  D.D.  and  Villee,  C.A.  1960.  Transport 
functions of the placenta. Physiol. Rev. 40, 313-
330. 
Hellmuth,  E.,  Damm,  P.  and  Molsted-Pedersen,  L. 
1994.  Congenital  malformations  in  offspring  of 
diabetic  women  treated  with  oral  hypoglycemic 
agents  during  embryogenesis.  Diabet.  Med.  11, 
471-474. 
Kato, H., Morishige, W.K. and Rotchild, I. 1979. A 
quantitative  relationship  between  the 
experimentally determined number of conceptuses 
and  corpus  luteum  activity  in  pregnant  rat. 
Endocrinology 105, 846-850. 
Khera, K.S. 1984. Maternal toxicity - a possible factor 
in fetal malformations in mice. Teratology 29(3), 
411-416. 
Langer,  O.  2002.  Oral  hypoglycemic  agents  and 
pregnant diabetic: “from bench to bedside”. Semin 
Perinatol. 26(3), 215-224. 
Langer,  O.,  Conway,  D.L.,  Berkus,  M.D.,  Xenakis, 
E.M.J. and Gonzales, O. 2000. A comparison of 
glyburide and insulin in women with gestacional 
diabetes mellitus. N. Engl. J. Med. 343(16), 1134-
1138. 
Larimore,  W.L.  and  Petrie,  K.A.  2000.  Drug  use 
during  pregnancy  and  lactation.  Update  in 
maternity care. Prim. Care 27(1), 35-53. 
Luiz, K.J., Maria, N.C.K., Marisa, P.Q., Mary, U.N. 
and  João,  A.V.M.  2011.  Farmacocinética, 
metabolismo e transferência de drogas. In: Briquet 
R,  Guariento  A,  editores.  Obstetrícia  normal.  1
st 
ed. Barueri: Manole. pp: 93-113. 
Maganha,  C.A.,  Vanni,  D.G.B.S.,  Bernardini,  M.A. 
and  Zugaib,  M.  2003.  Tratamento  do  diabetes 
melito gestacional. Rev. Assoc. Med. Bras. 49(3), 
330-334. 
Montenegro,  C.A.B.  and  Rezende  Filho,  J.  2008. 
Obstetrícia Fundamental. 11
th ed. Rio de Janeiro: 
Guanabara Koogan. 
Nery,  C.G.C.,  Pires,  M.A.S.,  Pianetti,  G.A.  and 
Vianna-Soares,  C.D.  2008.  Caracterização  do 
fármaco  hipoglicemiante  glibenclamida.  Rev. 
Bras. Ciênc. Farm. 44(1), 61-71. 
O`Sullivan,  J.B.,  Charles,  D.,  Mahan,  C.M.  and 
Dandrow,  R.V.  1973.  Gestational  diabetes  and 
perinatal  mortality  rate.  Am.  J.  Obstet.  Gynecol. 
116, 901-904. 
Rotondo, L. and Coustan, D.R. 1996. Diabetes mélito 
na  gestação.  In:  Knuppel  RA,  Drukker  JE, 
editores.  Alto  risco  em  obstetrícia:  um  enfoque 
multidisciplinar.  2
nd  ed.  Porto  Alegre:  Artes 
Médicas. 424-438. http://www.openveterinaryjournal.com 
L. Aguillar-Gomes et al.  Open Veterinary Journal, (2014), Vol. 4(1): 59-64 
________________________________________________________________________________________________________ 
  64 
Sen`kova,  A.V.,  Mironova,  N.L.,  Patutina,  O.A., 
Ageeva, T.A. and Zenkova, M.A. 2012. The toxic 
effects  of  polychemotherapy  onto  the  liver  are 
accelerated  by  the  up  regulated  MDR  of 
lymphosarcoma.  ISRN  Oncol.  1-15.doi: 
10.5402/2012/721612. 
Silva,  J.C.,  Bertini,  A.M.,  Taborda,  W.,  Becker,  F., 
Bebber,  F.R.L.,  Aquim,  G.M.D.C.  and  Viesi, 
J.M.Z.  2007a.  Glibenclamida  no  tratamento  do 
diabetes melito gestacional em estudo comparado à 
insulina. Arq. Bras. Endocrinol. Metab. 51(4), 541-
547. 
Silva,  J.C.,  Heinen,  A.,  Scheidt,  M.B.,  Marcondes, 
M.A.O. and Bertini, A.M. 2007b. Tratamento do 
diabetes  mellitus  gestacional  com  glibenclamida 
-  fatores   de   sucesso   e    resultados    perinatais.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rev.  Bras.  Ginecol.  Obstet.  29(11),  555-560. 
Uchida, K., Kadowaki, M., Nomura, Y., Miyata, K. 
and  Miyake,  T.  1970.  Relationship  between 
ovarian  progestin  secretion  and  corpora  lútea 
function in pregnant rat. Endocrinol. Jpn.  17(6), 
499-507. 
Valdés, R.E., Soto-Chacón, E., Lahsen, R.M., Barrera, 
C.H.  and  Candia,  P.P.  2008.  Eficacia  de  los 
hipoglicemiantes orales em el control metabólico 
de  pacientes  con  diabetes  mellitus  gestacional. 
Rev. Med. Chile 136(7), 915-920. 
Volpato,  G.T.,  Damasceno,  D.C.,  Campos,  K.E., 
Rocha,  R.,  Rudge,  M.V.C.  and  Calderon,  I.M.P. 
2006. Avaliação do efeito do exercício físico no 
metabolismo  de  ratas  diabéticas  prenhes.  Rev. 
Bras. Med. Esporte. 12(5), 229-233. 